These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22551628)

  • 21. Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.
    Velkov T; Rimmer KA; Headey SJ
    Protein Expr Purif; 2010 Apr; 70(2):260-9. PubMed ID: 19782138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A; Godio C; Laghezza A; Mitro N; Fracchiolla G; Tortorella V; Lavecchia A; Novellino E; Fruchart JC; Staels B; Crestani M; Loiodice F
    J Med Chem; 2005 Aug; 48(17):5509-19. PubMed ID: 16107150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
    Jakobsen MA; Petersen RK; Kristiansen K; Lange M; Lillevang ST
    Scand J Immunol; 2006 May; 63(5):330-7. PubMed ID: 16640656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Sheu SH; Kaya T; Waxman DJ; Vajda S
    Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization.
    Bernardes A; Souza PC; Muniz JR; Ricci CG; Ayers SD; Parekh NM; Godoy AS; Trivella DB; Reinach P; Webb P; Skaf MS; Polikarpov I
    J Mol Biol; 2013 Aug; 425(16):2878-93. PubMed ID: 23707408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid.
    Rieck M; Meissner W; Ries S; Müller-Brüsselbach S; Müller R
    Mol Pharmacol; 2008 Nov; 74(5):1269-77. PubMed ID: 18701617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
    Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
    Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
    J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR)α Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method.
    Oyama T; Kamata S; Ishii I; Miyachi H
    Biol Pharm Bull; 2021; 44(9):1202-1209. PubMed ID: 34471048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha.
    Cho MC; Lee S; Choi HS; Yang Y; Tae Hong J; Kim SJ; Yoon DY
    Immunopharmacol Immunotoxicol; 2009; 31(3):459-67. PubMed ID: 19263263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity.
    Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB
    Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
    Miyachi H
    IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo.
    Ham J; Hwang H; Kim E; Kim JA; Cho SJ; Ko J; Lee W; Lee J; Holla H; Banerjee J; Kim S; Yang I; Lee HJ; Shin K; Choi H; Nam SJ; Tak J; Hahn D; Oh T; Won DH; Lee TG; Choi J; Park MS; Seok C; Chin J; Kang H
    Eur J Med Chem; 2012 Jul; 53():190-202. PubMed ID: 22534184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Okazaki S; Shioi R; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2016 Nov; 24(21):5455-5461. PubMed ID: 27622746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise.
    Kannisto K; Chibalin A; Glinghammar B; Zierath JR; Hamsten A; Ehrenborg E
    Int J Mol Med; 2006 Jan; 17(1):45-52. PubMed ID: 16328010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids.
    Fyffe SA; Alphey MS; Buetow L; Smith TK; Ferguson MA; Sørensen MD; Björkling F; Hunter WN
    J Mol Biol; 2006 Mar; 356(4):1005-13. PubMed ID: 16405912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist.
    Naruhn S; Meissner W; Adhikary T; Kaddatz K; Klein T; Watzer B; Müller-Brüsselbach S; Müller R
    Mol Pharmacol; 2010 Feb; 77(2):171-84. PubMed ID: 19903832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.